About Medfiniti
Medfiniti is a medical technology platform company built around treatment technology, recurring procedure-based revenue, and disciplined operating execution.
Not a device company. A platform company.
Medfiniti is organized as a medical technology platform company rather than a single-product device manufacturer. The company integrates intellectual property, operating infrastructure, and clinical deployment within a unified structure designed to support recurring revenue and long-term platform development.
Its current operating platform, HemWell MD, serves as the company's initial commercial proof point and operating foundation for future growth.
Current operating scale
From Ultroid to Medfiniti
The current Medfiniti platform originated from direct current electrolysis technology first developed in the late 1990s. Following the acquisition of the technology and patents in 2021, Medfiniti rebuilt the operating model, device architecture, quality systems, and commercialization approach into the platform in place today.
Ultroid Technology Era
Direct current electrolysis technology developed, receiving CE approval (1996) and FDA clearance (1999). Successfully deployed in clinical practice for over 15 years, treating an estimated 155,000+ procedures.
Medfiniti, Inc. Founded & IP Acquired
Medfiniti, Inc. incorporated and acquired the core intellectual property and patent portfolio. The company began comprehensive restructuring, including quality system remediation and regulatory pathway development.
Gen 1 R&D
HemWell MD created. Complete redesign of device architecture, quality management systems, and operating model, culminating in FDA 510(k) clearance.
Gen 1 Trial Launch
Gen 1 device launched, introducing the initial commercialization framework and beginning clinical deployment.
Gen 2 R&D and Corporate Platform Reorganization
Development of enhanced Gen 2 device architecture, incorporating connectivity improvements, updated platform infrastructure, and expanded clinical capabilities. Medfiniti, Inc. underwent a corporate reorganization to establish its current platform architecture: Medfiniti, Inc. (Parent) → Medfiniti IP, LLC (IP) → HemWell MD International, Inc. (Global Management) → regional operating subsidiaries (HemWell MD, Inc. – North America, HemWell MD GOV – Government & Military, HemWell MD B.V. – E.U./U.K., HemWell MD GCC – Middle East).
Gen 2 Trial Launch and Replacement of Gen 1s
HemWell Gen 2 launched nationally in February 2026 with enhanced device architecture and connectivity. Full replacement of Gen 1 systems underway across 51 active centers with 40,000+ cumulative procedures performed.
Government & Military Launch — VA Hospitals
HemWell MD GOV is launching its Government & Military division in Q3 2026, targeting VA Hospital systems across the United States. This initiative brings the HemWell MD procedure to veterans through an established government contracting framework.
Platform Expansion — Middle East, EU & Gen 3
Medfiniti is targeting the commercial launch of HemWell MD B.V. across the European Union and HemWell MD GCC across the Middle East in 2027, leveraging established regional management and regulatory pathways. In parallel, Gen 3 is in development and planned to revolutionize hemorrhoid treatment through a completely new delivery system — designed to expand the total addressable market 8–10x while extending operating, data, and clinical capabilities.
Why the current model works
Medfiniti's current operating success reflects more than inherited technology. It reflects changes in procedure design, reimbursement alignment, customer targeting, device architecture, and business model.
Procedure Model
The current platform incorporates anesthesia and a one-and-done treatment concept, improving patient completion and reducing the need for multiple return visits.
Coding and Reimbursement
The operating model is structured around appropriate use of CPT ligation codes, improving the commercial viability of the procedure for physician practices.
Target Customer
HemWell MD is commercialized primarily to gastroenterologists, rather than the earlier physician targeting strategy used by the predecessor system.
Technology Platform
The Gen 2 device introduced updated technology architecture, including connectivity enhancements and a stronger foundation for future platform development.
Business Model
The company provides the device without upfront capital cost and monetizes through per-procedure usage, materially changing the adoption model relative to the predecessor system.
Our team
Michael J. Goeree, MBA
CEO / Chairman
Medfiniti, Inc.
Stephen Goldman, MD, FACC
CMO / Vice Chairman
Medfiniti, Inc.
Matt Totty
Chief Financial Officer
Medfiniti, Inc.
Cedric E. Lewis, JD, MBA
President / Governance
Medfiniti IP, LLC
Reed Hogan III, MD, FACG
Medical Director
HemWell MD International
Mitch Weiner
VP Sales
HemWell MD
Clyde Hubbard
President & Managing Director
HemWell MD GOV
Harro Schulz, LL.M.
International Executive Director
HemWell MD B.V. (Europe & GCC)
Samantha Paolitto
Administrative Director
Medfiniti, Inc.
Medfiniti is building a platform company around clinical technology, operating infrastructure, and recurring procedure-based economics.
Current operating platform: HemWell MD